Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
